J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
11 Jun 2024
Immunotherapy
Preview
Source: Pharmaceutical Technology
Along with advancing BPT567, Bright Peak said the funds will go towards accelerating its wider pipeline. Image credit: Shutterstock / SFIO CRACHO.
Bright Peak Therapeutics has raised $90m in a Series C financing round as the biotech looks to make a name for itself in the immunoconjugate space.
Recommended Buyer's Guides
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
Johnson and Johnson’s (J&J) investment arm JJDC led the Series C round backing Bright Peak’s cancer treatment portfolio, which also saw participation from new investors Venrock, KB Investment, and Northleaf Capital Partners.
Bright Peak said the funds will be used to advance its lead asset – BPT567 – into a Phase I/IIa clinical trial for the treatment of solid tumours, according to an 11 June press release. BPT567 is a PD1-IL18 immunoconjugate – an IL-18 binding protein-resistant molecule integrated with PD-1 checkpoint blockade using “antibody drug conjugate-like” technology.
The biotech, which has offices in both Switzerland and the US, claims BPT567 is the first immunoconjugate of its kind to enter the clinic. The Phase I/IIa study is slated to begin in the second half of this year.
Targeting IL-18 increases the activation and cytotoxicity of antigen-experienced effector T cells in the tumour microenvironment. Coupled with unlocking the body’s anti-tumour response via PD-1 blockade, BPT567 induced “profound synergistic anti-tumour activity” in preclinical models, according to Bright Peak.
See Also:Takeda signs option agreement with Ascentage for CML drug
Preview
Source: Pharmaceutical Technology
UK’s new Netflix-style funding model for antibiotics goes live
Preview
Source: Pharmaceutical Technology
Along with advancing BPT567 into early trials, Bright Peak said the funds will also go towards accelerating its wider pipeline of next-generation immunotherapies.
The PD-1 inhibitorPD-1 inhibitor landscape is currently dominated by MSD’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab). Last year, Keytruda generated $25bn in sales while Opdivo accumulated $9bn in revenue.
Meanwhile, the promise of using IL-18 in cancer therapies is growing steadily. Gilead Sciences gained ground in the space when it acquired the rights to Compugen’s preclinical IL-18 binding protein programme late last year in a deal that could reach $848m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.